{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T23:19:50Z","timestamp":1788391190155,"version":"build-2803163510"},"reference-count":111,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T00:00:00Z","timestamp":1788393600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T00:00:00Z","timestamp":1788393600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["PNRR-MAD-2022-12375663"],"award-info":[{"award-number":["PNRR-MAD-2022-12375663"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["Ricerca Corrente CRO-Aviano linea 1"],"award-info":[{"award-number":["Ricerca Corrente CRO-Aviano linea 1"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["RF-2021-12371961"],"award-info":[{"award-number":["RF-2021-12371961"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003407","name":"Ministero dell'Istruzione, dell'Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","award":["ARS01_00568"],"award-info":[{"award-number":["ARS01_00568"]}],"id":[{"id":"10.13039\/501100003407","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009874","name":"Regione Autonoma Friuli Venezia Giulia","doi-asserted-by":"publisher","award":["L.R. 22\/2022 for the RESTART-OV project"],"award-info":[{"award-number":["L.R. 22\/2022 for the RESTART-OV project"]}],"id":[{"id":"10.13039\/501100009874","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","award":["IG 26253"],"award-info":[{"award-number":["IG 26253"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","award":["MFAG 28993"],"award-info":[{"award-number":["MFAG 28993"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","award":["Abroad Pre-doc fellowship"],"award-info":[{"award-number":["Abroad Pre-doc fellowship"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","award":["MFAG 24321"],"award-info":[{"award-number":["MFAG 24321"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]},{"name":"CRO Aviano 5\u2030 intramural grant."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sig Transduct Target Ther"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Epithelial ovarian cancer (EOC) is a highly lethal disease characterized by a high rate of platinum (PT)-resistant recurrence. Dysregulation of transcriptional and alternative splicing (AS) has been suggested as a possible mechanism of PT resistance involving transcriptional cyclin-dependent kinases (CDKs). We report that pharmacological CDK12\/CDK13 inhibition (CDK12i) synergistically enhances PT-induced cytotoxicity in a large number of PT-sensitive and PT-resistant EOC models. CDK12i effectively delayed the emergence of PT-resistant recurrences in vitro and in vivo. Acquired resistance to CDK12i enhanced PT sensitivity, revealing a therapeutically exploitable vulnerability to PT. CDK12i strongly reshapes transcriptional elongation and RNA processing, impacting multiple categories of AS, with marked enrichment of transcripts involved in the DNA damage repair (DDR) pathway. We proved that CDK12 interacts with the splicing master regulator SFPQ\/p54\n                    <jats:sup>nrb<\/jats:sup>\n                    complex, driving its distribution in transcriptional condensates. The p54\n                    <jats:sup>nrb<\/jats:sup>\n                    subunit of the complex is required for the CDK12-SFPQ interaction and to ensure splicing reprogramming and CDK12i-induced cytotoxicity in all the EOC models tested. The use of CT7439, a novel clinical-grade CDK12i, which is now in phase I\/II clinical trials, confirmed the therapeutic potential of CDK12i, either as monotherapy or in combination with PT. These findings emphasize that the therapeutic potential of CDK12i extends beyond DDR regulation, encompassing a critical role in RNA processing and AS. This dual impact affects EOC survival and may provide a novel, clinically relevant therapeutic strategy for hard-to-treat PT-resistant patients for whom effective treatment options remain limited.\n                  <\/jats:p>","DOI":"10.1038\/s41392-026-02932-w","type":"journal-article","created":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T23:01:35Z","timestamp":1788390095000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["CDK12\/13 inhibition overcomes platinum resistance by impairing RNA metabolism"],"prefix":"10.1038","volume":"11","author":[{"given":"Ilenia","family":"Pellarin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-9264-1499","authenticated-orcid":false,"given":"Valentina","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo Giuseppe","family":"Margiotta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3031-7917","authenticated-orcid":false,"given":"Javad","family":"Karimbayli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessio","family":"Polacchini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashwani","family":"Bahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milena","family":"Nicoloso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maura","family":"Sonego","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"D\u2019Andrea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-0837-6268","authenticated-orcid":false,"given":"Laura","family":"Sala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Canesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6053-8182","authenticated-orcid":false,"given":"Andrea","family":"Favero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-0294-8667","authenticated-orcid":false,"given":"Anna","family":"Nespolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danilo","family":"Licastro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Bartoletti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0573-4938","authenticated-orcid":false,"given":"Fabio","family":"Puglisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonino","family":"Ditto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Canzonieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Schiappacassi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9387-7586","authenticated-orcid":false,"given":"Iain","family":"McNeish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Sanguinetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Belletti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9750-8825","authenticated-orcid":false,"given":"Gustavo","family":"Baldassarre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,3]]},"reference":[{"key":"2932_CR1","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1016\/S0140-6736(18)32552-2","volume":"393","author":"S Lheureux","year":"2019","unstructured":"Lheureux, S., Gourley, C., Vergote, I. & Oza, A. M. Epithelial ovarian cancer. Lancet Lond. Engl. 393, 1240\u20131253 (2019).","journal-title":"Lancet Lond. Engl."},{"key":"2932_CR2","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1016\/S0140-6736(13)62146-7","volume":"384","author":"GC Jayson","year":"2014","unstructured":"Jayson, G. C., Kohn, E. C., Kitchener, H. C. & Ledermann, J. A. Ovarian cancer. Lancet Lond. Engl. 384, 1376\u20131388 (2014).","journal-title":"Lancet Lond. Engl."},{"key":"2932_CR3","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1016\/j.annonc.2020.06.004","volume":"31","author":"MR Mirza","year":"2020","unstructured":"Mirza, M. R. et al. The forefront of ovarian cancer therapy: update on PARP inhibitors. Ann. Oncol. J. Eur. Soc. Med. Oncol. 31, 1148\u20131159 (2020).","journal-title":"Ann. Oncol. J. Eur. Soc. Med. Oncol."},{"key":"2932_CR4","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1056\/NEJMoa1911361","volume":"381","author":"I Ray-Coquard","year":"2019","unstructured":"Ray-Coquard, I. et al. Olaparib plus bevacizumab as first-line maintenance in ovarian cancer. N. Engl. J. Med. 381, 2416\u20132428 (2019).","journal-title":"N. Engl. J. Med."},{"key":"2932_CR5","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1038\/s41571-021-00532-x","volume":"18","author":"MP Dias","year":"2021","unstructured":"Dias, M. P., Moser, S. C., Ganesan, S. & Jonkers, J. Understanding and overcoming resistance to PARP inhibitors in cancer therapy. Nat. Rev. Clin. Oncol. 18, 773\u2013791 (2021).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2932_CR6","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/j.cell.2016.12.013","volume":"168","author":"JE Bradner","year":"2017","unstructured":"Bradner, J. E., Hnisz, D. & Young, R. A. Transcriptional addiction in cancer. Cell 168, 629\u2013643 (2017).","journal-title":"Cell"},{"key":"2932_CR7","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-025-02339-1","volume":"24","author":"G Baldassarre","year":"2025","unstructured":"Baldassarre, G., de la Serna, I. L. & Vallette, F. M. Death-ision: the link between cellular resilience and cancer resistance to treatments. Mol. Cancer 24, 144 (2025).","journal-title":"Mol. Cancer"},{"key":"2932_CR8","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.15252\/emmm.201607012","volume":"9","author":"A Dall\u2019Acqua","year":"2017","unstructured":"Dall\u2019Acqua, A. et al. CDK6 protects epithelial ovarian cancer from platinum-induced death via FOXO3 regulation. EMBO Mol. Med. 9, 1415\u20131433 (2017).","journal-title":"EMBO Mol. Med."},{"key":"2932_CR9","doi-asserted-by":"crossref","unstructured":"The Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature 474, 609\u2013615 (2011).","DOI":"10.1038\/nature10166"},{"key":"2932_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41419-022-05347-x","volume":"13","author":"R Coelho","year":"2022","unstructured":"Coelho, R. et al. Overlapping gene dependencies for PARP inhibitors and carboplatin response identified by functional CRISPR-Cas9 screening in ovarian cancer. Cell Death Dis. 13, 1\u201313 (2022).","journal-title":"Cell Death Dis."},{"key":"2932_CR11","first-page":"1","volume":"10","author":"I Pellarin","year":"2025","unstructured":"Pellarin, I. et al. Cyclin-dependent protein kinases and cell cycle regulation in biology and disease. Signal Transduct. Target. Ther. 10, 1\u201362 (2025).","journal-title":"Signal Transduct. Target. Ther."},{"key":"2932_CR12","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1158\/0008-5472.CAN-20-2245","volume":"81","author":"H Liu","year":"2021","unstructured":"Liu, H., Liu, K. & Dong, Z. Targeting CDK12 for cancer therapy: function, mechanism, and drug discovery. Cancer Res. 81, 18\u201326 (2021).","journal-title":"Cancer Res."},{"key":"2932_CR13","doi-asserted-by":"publisher","DOI":"10.1186\/s13008-017-0033-x","volume":"12","author":"H Paculov\u00e1","year":"2017","unstructured":"Paculov\u00e1, H. & Kohoutek, J. The emerging roles of CDK12 in tumorigenesis. Cell Div. 12, 7 (2017).","journal-title":"Cell Div."},{"key":"2932_CR14","doi-asserted-by":"publisher","first-page":"4691","DOI":"10.1128\/MCB.06267-11","volume":"32","author":"S-WG Cheng","year":"2012","unstructured":"Cheng, S.-W. G. et al. Interaction of cyclin-dependent kinase 12\/CrkRS with cyclin K1 Is required for the phosphorylation of the C-terminal domain of RNA polymerase II. Mol. Cell. Biol. 32, 4691\u20134704 (2012).","journal-title":"Mol. Cell. Biol."},{"key":"2932_CR15","doi-asserted-by":"publisher","first-page":"2303","DOI":"10.1101\/gad.1968210","volume":"24","author":"B Bartkowiak","year":"2010","unstructured":"Bartkowiak, B. et al. CDK12 is a transcription elongation-associated CTD kinase, the metazoan ortholog of yeast Ctk1. Genes Dev. 24, 2303\u20132316 (2010).","journal-title":"Genes Dev."},{"key":"2932_CR16","doi-asserted-by":"publisher","DOI":"10.15252\/embr.201847592","volume":"20","author":"AP Chirackal Manavalan","year":"2019","unstructured":"Chirackal Manavalan, A. P. et al. CDK12 controls G1\/S progression by regulating RNAPII processivity at core DNA replication genes. EMBO Rep. 20, e47592 (2019).","journal-title":"EMBO Rep."},{"key":"2932_CR17","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1158\/2159-8290.CD-19-0528","volume":"10","author":"J Chou","year":"2020","unstructured":"Chou, J., Quigley, D. A., Robinson, T. M., Feng, F. Y. & Ashworth, A. Transcription-associated cyclin-dependent kinases as targets and biomarkers for cancer therapy. Cancer Discov. 10, 351\u2013370 (2020).","journal-title":"Cancer Discov."},{"key":"2932_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-09703-y","volume":"10","author":"M Krajewska","year":"2019","unstructured":"Krajewska, M. et al. CDK12 loss in cancer cells affects DNA damage response genes through premature cleavage and polyadenylation. Nat. Commun. 10, 1757 (2019).","journal-title":"Nat. Commun."},{"key":"2932_CR19","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1038\/s41586-018-0758-y","volume":"564","author":"SJ Dubbury","year":"2018","unstructured":"Dubbury, S. J., Boutz, P. L. & Sharp, P. A. Cdk12 regulates DNA repair genes by suppressing intronic polyadenylation. Nature 564, 141\u2013145 (2018).","journal-title":"Nature"},{"key":"2932_CR20","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2426909122","volume":"122","author":"JC-Y Tien","year":"2025","unstructured":"Tien, J. C.-Y. et al. Defining CDK12 as a tumor suppressor and therapeutic target in mouse models of tubo-ovarian high-grade serous carcinoma. Proc. Natl. Acad. Sci. USA 122, e2426909122 (2025).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2932_CR21","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1158\/0008-5472.CAN-13-2541","volume":"74","author":"I Bajrami","year":"2014","unstructured":"Bajrami, I. et al. Genome-wide profiling of genetic synthetic lethality identifies CDK12 as a novel determinant of PARP1\/2 inhibitor sensitivity. Cancer Res. 74, 287\u2013297 (2014).","journal-title":"Cancer Res."},{"key":"2932_CR22","doi-asserted-by":"publisher","first-page":"102485","DOI":"10.1016\/j.coph.2024.102485","volume":"79","author":"R Roy","year":"2024","unstructured":"Roy, R., Gampa, S. C. & Garimella, S. V. Role of specific CDKs in regulating DNA damage repair responses and replication stress. Curr. Opin. Pharmacol. 79, 102485 (2024).","journal-title":"Curr. Opin. Pharmacol."},{"key":"2932_CR23","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1038\/nchembio.2166","volume":"12","author":"T Zhang","year":"2016","unstructured":"Zhang, T. et al. Covalent targeting of remote cysteine residues to develop CDK12 and CDK13 inhibitors. Nat. Chem. Biol. 12, 876\u2013884 (2016).","journal-title":"Nat. Chem. Biol."},{"key":"2932_CR24","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/j.ccell.2019.09.004","volume":"36","author":"V Quereda","year":"2019","unstructured":"Quereda, V. et al. Therapeutic Targeting of CDK12\/CDK13 in Triple-Negative Breast Cancer. Cancer Cell 36, 545\u2013558.e7 (2019).","journal-title":"Cancer Cell"},{"key":"2932_CR25","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1093\/jnci\/djaf295","volume":"118","author":"D Ottaviani","year":"2026","unstructured":"Ottaviani, D. et al. Targeting CDK12 disrupts estrogen-receptor chromatin recruitment and ER-MED1 transcription in advanced ER+ breast cancer. JNCI J. Natl. Cancer Inst. 118, 404\u2013421 (2026).","journal-title":"JNCI J. Natl. Cancer Inst."},{"key":"2932_CR26","doi-asserted-by":"publisher","first-page":"7004","DOI":"10.1158\/1538-7445.AM2025-7004","volume":"85","author":"AK Bahl","year":"2025","unstructured":"Bahl, A. K. et al. Abstract 7004: CT7439 an oral first-in class selective CDK12 and 13 inhibitor and cyclin K degrader: Profiling activity and combination efficacy in an ovarian cancer model. Cancer Res. 85, 7004 (2025).","journal-title":"Cancer Res."},{"key":"2932_CR27","doi-asserted-by":"publisher","first-page":"2738","DOI":"10.1016\/j.molcel.2022.05.010","volume":"82","author":"T Yasuhara","year":"2022","unstructured":"Yasuhara, T. et al. Condensates induced by transcription inhibition localize active chromatin to nucleoli. Mol. Cell 82, 2738\u20132753.e6 (2022).","journal-title":"Mol. Cell"},{"key":"2932_CR28","doi-asserted-by":"publisher","first-page":"115904","DOI":"10.1016\/j.celrep.2025.115904","volume":"44","author":"O Luyties","year":"2025","unstructured":"Luyties, O. et al. Multi-omics and biochemical reconstitution reveal CDK7-dependent mechanisms controlling RNA polymerase II function at gene 5\u2019- and 3\u2019 ends. Cell Rep. 44, 115904 (2025).","journal-title":"Cell Rep."},{"key":"2932_CR29","doi-asserted-by":"publisher","first-page":"4390","DOI":"10.1038\/s41388-020-1292-6","volume":"39","author":"I Pellarin","year":"2020","unstructured":"Pellarin, I. et al. Splicing factor proline- and glutamine-rich (SFPQ) protein regulates platinum response in ovarian cancer-modulating SRSF2 activity. Oncogene 39, 4390\u20134403 (2020).","journal-title":"Oncogene"},{"key":"2932_CR30","doi-asserted-by":"publisher","first-page":"3989","DOI":"10.1093\/nar\/gkw271","volume":"44","author":"GJ Knott","year":"2016","unstructured":"Knott, G. J., Bond, C. S. & Fox, A. H. The DBHS proteins SFPQ, NONO and PSPC1: a multipurpose molecular scaffold. Nucleic Acids Res. 44, 3989\u20134004 (2016).","journal-title":"Nucleic Acids Res."},{"key":"2932_CR31","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1101\/gad.1565207","volume":"21","author":"S Kaneko","year":"2007","unstructured":"Kaneko, S., Rozenblatt-Rosen, O., Meyerson, M. & Manley, J. L. The multifunctional protein p54nrb\/PSF recruits the exonuclease XRN2 to facilitate pre-mRNA 3\u2019 processing and transcription termination. Genes Dev. 21, 1779\u20131789 (2007).","journal-title":"Genes Dev."},{"key":"2932_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-04373-8","volume":"9","author":"R Luisier","year":"2018","unstructured":"Luisier, R. et al. Intron retention and nuclear loss of SFPQ are molecular hallmarks of ALS. Nat. Commun. 9, 2010 (2018).","journal-title":"Nat. Commun."},{"key":"2932_CR33","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1016\/j.celrep.2018.03.141","volume":"23","author":"A Takeuchi","year":"2018","unstructured":"Takeuchi, A. et al. Loss of Sfpq causes long-gene transcriptopathy in the brain. Cell Rep. 23, 1326\u20131341 (2018).","journal-title":"Cell Rep."},{"key":"2932_CR34","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.isci.2019.02.023","volume":"13","author":"M Hosokawa","year":"2019","unstructured":"Hosokawa, M. et al. Loss of RNA-Binding Protein Sfpq causes long-gene transcriptopathy in skeletal muscle and severe muscle mass reduction with metabolic myopathy. iScience 13, 229\u2013242 (2019).","journal-title":"iScience"},{"key":"2932_CR35","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1158\/1535-7163.MCT-23-0677","volume":"24","author":"A Kolodziejczyk","year":"2025","unstructured":"Kolodziejczyk, A. & Sicinski, P. Targeting transcriptional cyclin-dependent kinases in cancer. Mol. Cancer Ther. 24, 1497\u20131510 (2025).","journal-title":"Mol. Cancer Ther."},{"key":"2932_CR36","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1186\/s13046-023-02682-5","volume":"42","author":"E Cesari","year":"2023","unstructured":"Cesari, E. et al. Dual inhibition of CDK12 and CDK13 uncovers actionable vulnerabilities in patient-derived ovarian cancer organoids. J. Exp. Clin. Cancer Res. 42, 126 (2023).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"2932_CR37","doi-asserted-by":"publisher","first-page":"3588","DOI":"10.1158\/0008-5472.CAN-22-0222","volume":"82","author":"L Cheng","year":"2022","unstructured":"Cheng, L. et al. Dual inhibition of CDK12\/CDK13 targets both tumor and immune cells in ovarian cancer. Cancer Res. 82, 3588\u20133602 (2022).","journal-title":"Cancer Res."},{"key":"2932_CR38","doi-asserted-by":"publisher","first-page":"1387281","DOI":"10.3389\/fonc.2024.1387281","volume":"14","author":"N Stiegeler","year":"2024","unstructured":"Stiegeler, N. et al. Homologous recombination proficient subtypes of high-grade serous ovarian cancer: treatment options for a poor prognosis group. Front. Oncol. 14, 1387281 (2024).","journal-title":"Front. Oncol."},{"key":"2932_CR39","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adp6567","volume":"10","author":"A Nespolo","year":"2024","unstructured":"Nespolo, A. et al. USP1 deubiquitinates PARP1 to regulate its trapping and PARylation activity. Sci. Adv. 10, eadp6567 (2024).","journal-title":"Sci. Adv."},{"key":"2932_CR40","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1038\/s44321-024-00069-3","volume":"16","author":"A Gambelli","year":"2024","unstructured":"Gambelli, A. et al. Platinum-induced upregulation of ITGA6 promotes chemoresistance and spreading in ovarian cancer. EMBO Mol. Med. 16, 1162\u20131192 (2024).","journal-title":"EMBO Mol. Med."},{"key":"2932_CR41","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-07005-1","volume":"7","author":"M Sonego","year":"2017","unstructured":"Sonego, M. et al. Common biological phenotypes characterize the acquisition of platinum-resistance in epithelial ovarian cancer cells. Sci. Rep. 7, 7104 (2017).","journal-title":"Sci. Rep."},{"key":"2932_CR42","doi-asserted-by":"publisher","first-page":"6118","DOI":"10.1158\/0008-5472.CAN-16-1272","volume":"76","author":"J Walton","year":"2016","unstructured":"Walton, J. et al. CRISPR\/Cas9-mediated Trp53 and Brca2 knockout to generate improved murine models of ovarian high-grade serous carcinoma. Cancer Res. 76, 6118\u20136129 (2016).","journal-title":"Cancer Res."},{"key":"2932_CR43","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-17119-1","volume":"7","author":"JB Walton","year":"2017","unstructured":"Walton, J. B. et al. CRISPR\/Cas9-derived models of ovarian high grade serous carcinoma targeting Brca1, Pten and Nf1, and correlation with platinum sensitivity. Sci. Rep. 7, 16827 (2017).","journal-title":"Sci. Rep."},{"key":"2932_CR44","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aav3235","volume":"5","author":"M Sonego","year":"2019","unstructured":"Sonego, M. et al. USP1 links platinum resistance to cancer cell dissemination by regulating Snail stability. Sci. Adv. 5, eaav3235 (2019).","journal-title":"Sci. Adv."},{"key":"2932_CR45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.canlet.2019.05.032","volume":"459","author":"C Kreuzinger","year":"2019","unstructured":"Kreuzinger, C. et al. Patient-derived cell line models revealed therapeutic targets and molecular mechanisms underlying disease progression of high grade serous ovarian cancer. Cancer Lett. 459, 1\u201312 (2019).","journal-title":"Cancer Lett."},{"key":"2932_CR46","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1101\/gad.349431.122","volume":"36","author":"JL Hopkins","year":"2022","unstructured":"Hopkins, J. L., Lan, L. & Zou, L. DNA repair defects in cancer and therapeutic opportunities. Genes Dev. 36, 278\u2013293 (2022).","journal-title":"Genes Dev."},{"key":"2932_CR47","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1038\/s41392-023-01548-8","volume":"8","author":"Q Li","year":"2023","unstructured":"Li, Q. et al. A new wave of innovations within the DNA damage response. Signal Transduct. Target. Ther. 8, 338 (2023).","journal-title":"Signal Transduct. Target. Ther."},{"key":"2932_CR48","doi-asserted-by":"publisher","first-page":"R1287","DOI":"10.1016\/j.cub.2017.10.044","volume":"27","author":"C Janke","year":"2017","unstructured":"Janke, C. & Montagnac, G. Causes and consequences of microtubule acetylation. Curr. Biol. 27, R1287\u2013R1292 (2017).","journal-title":"Curr. Biol."},{"key":"2932_CR49","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1038\/nrc1317","volume":"4","author":"MA Jordan","year":"2004","unstructured":"Jordan, M. A. & Wilson, L. Microtubules as a target for anticancer drugs. Nat. Rev. Cancer 4, 253\u2013265 (2004).","journal-title":"Nat. Rev. Cancer"},{"key":"2932_CR50","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1038\/nsmb1314","volume":"14","author":"GE Damsma","year":"2007","unstructured":"Damsma, G. E., Alt, A., Brueckner, F., Carell, T. & Cramer, P. Mechanism of transcriptional stalling at cisplatin-damaged DNA. Nat. Struct. Mol. Biol. 14, 1127\u20131133 (2007).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"2932_CR51","doi-asserted-by":"publisher","first-page":"3018","DOI":"10.1093\/nar\/gkac174","volume":"50","author":"A Agapov","year":"2022","unstructured":"Agapov, A., Olina, A. & Kulbachinskiy, A. RNA polymerase pausing, stalling and bypass during transcription of damaged DNA: from molecular basis to functional consequences. Nucleic Acids Res. 50, 3018\u20133041 (2022).","journal-title":"Nucleic Acids Res."},{"key":"2932_CR52","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1002\/med.21741","volume":"41","author":"I Pellarin","year":"2021","unstructured":"Pellarin, I., Belletti, B. & Baldassarre, G. RNA splicing alteration in the response to platinum chemotherapy in ovarian cancer: a possible biomarker and therapeutic target. Med. Res. Rev. 41, 586\u2013615 (2021).","journal-title":"Med. Res. Rev."},{"key":"2932_CR53","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1038\/nprot.2008.211","volume":"4","author":"DW Huang","year":"2009","unstructured":"Huang, D. W., Sherman, B. T. & Lempicki, R. A. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat. Protoc. 4, 44\u201357 (2009).","journal-title":"Nat. Protoc."},{"key":"2932_CR54","doi-asserted-by":"publisher","first-page":"W216","DOI":"10.1093\/nar\/gkac194","volume":"50","author":"BT Sherman","year":"2022","unstructured":"Sherman, B. T. et al. DAVID: a web server for functional enrichment analysis and functional annotation of gene lists (2021 update). Nucleic Acids Res. 50, W216\u2013W221 (2022).","journal-title":"Nucleic Acids Res."},{"key":"2932_CR55","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1007\/s10585-021-10136-5","volume":"39","author":"D Dhaliwal","year":"2022","unstructured":"Dhaliwal, D. & Shepherd, T. G. Molecular and cellular mechanisms controlling integrin-mediated cell adhesion and tumor progression in ovarian cancer metastasis: a review. Clin. Exp. Metastasis 39, 291\u2013301 (2022).","journal-title":"Clin. Exp. Metastasis"},{"key":"2932_CR56","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.semcancer.2020.12.024","volume":"77","author":"A Ghoneum","year":"2021","unstructured":"Ghoneum, A. et al. Exploring the clinical value of tumor microenvironment in platinum-resistant ovarian cancer. Semin. Cancer Biol. 77, 83\u201398 (2021).","journal-title":"Semin. Cancer Biol."},{"key":"2932_CR57","doi-asserted-by":"publisher","first-page":"6395","DOI":"10.1038\/s41388-021-02055-2","volume":"40","author":"D Huang","year":"2021","unstructured":"Huang, D. et al. A highly annotated database of genes associated with platinum resistance in cancer. Oncogene 40, 6395\u20136405 (2021).","journal-title":"Oncogene"},{"key":"2932_CR58","doi-asserted-by":"publisher","first-page":"2158","DOI":"10.1101\/gad.16962311","volume":"25","author":"D Blazek","year":"2011","unstructured":"Blazek, D. et al. The Cyclin K\/Cdk12 complex maintains genomic stability via regulation of expression of DNA damage response genes. Genes Dev. 25, 2158\u20132172 (2011).","journal-title":"Genes Dev."},{"key":"2932_CR59","doi-asserted-by":"publisher","first-page":"105030","DOI":"10.1016\/j.isci.2022.105030","volume":"25","author":"B Magnuson","year":"2022","unstructured":"Magnuson, B. et al. CDK12 regulates co-transcriptional splicing and RNA turnover in human cells. iScience 25, 105030 (2022).","journal-title":"iScience"},{"key":"2932_CR60","doi-asserted-by":"publisher","first-page":"1952","DOI":"10.1016\/j.molcel.2025.04.012","volume":"85","author":"D Lopez Martinez","year":"2025","unstructured":"Lopez Martinez, D. et al. PAF1C-mediated activation of CDK12\/13 kinase activity is critical for CTD phosphorylation and transcript elongation. Mol. Cell 85, 1952\u20131967.e8 (2025).","journal-title":"Mol. Cell"},{"key":"2932_CR61","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1038\/s44321-026-00393-w","volume":"18","author":"S Lier","year":"2026","unstructured":"Lier, S. et al. CDK12\/CDK13 inhibition disrupts transcriptional elongation and replication fork progression in glioblastoma. EMBO Mol. Med. 18, 1592\u20131624 (2026).","journal-title":"EMBO Mol. Med."},{"key":"2932_CR62","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1038\/nrm.2017.130","volume":"19","author":"MW Hentze","year":"2018","unstructured":"Hentze, M. W., Castello, A., Schwarzl, T. & Preiss, T. A brave new world of RNA-binding proteins. Nat. Rev. Mol. Cell Biol. 19, 327\u2013341 (2018).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"2932_CR63","doi-asserted-by":"publisher","first-page":"7151","DOI":"10.3390\/ijms21197151","volume":"21","author":"YW Lim","year":"2020","unstructured":"Lim, Y. W., James, D., Huang, J. & Lee, M. The Emerging Role of the RNA-Binding Protein SFPQ in Neuronal Function and Neurodegeneration. Int. J. Mol. Sci. 21, 7151 (2020).","journal-title":"Int. J. Mol. Sci."},{"key":"2932_CR64","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/s41586-024-07487-w","volume":"630","author":"J Abramson","year":"2024","unstructured":"Abramson, J. et al. Accurate structure prediction of biomolecular interactions with AlphaFold 3. Nature 630, 493\u2013500 (2024).","journal-title":"Nature"},{"key":"2932_CR65","doi-asserted-by":"publisher","first-page":"5445","DOI":"10.1158\/1078-0432.CCR-23-3785","volume":"30","author":"J Chou","year":"2024","unstructured":"Chou, J. et al. Synthetic Lethal Targeting of CDK12-Deficient Prostate Cancer with PARP Inhibitors. Clin. Cancer Res. 30, 5445\u20135458 (2024).","journal-title":"Clin. Cancer Res."},{"key":"2932_CR66","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.cell.2022.12.013","volume":"186","author":"H Lyons","year":"2023","unstructured":"Lyons, H. et al. Functional partitioning of transcriptional regulators by patterned charge blocks. Cell 186, 327\u2013345.e28 (2023).","journal-title":"Cell"},{"key":"2932_CR67","doi-asserted-by":"publisher","first-page":"W488","DOI":"10.1093\/nar\/gkw409","volume":"44","author":"N Malhis","year":"2016","unstructured":"Malhis, N., Jacobson, M. & Gsponer, J. MoRFchibi SYSTEM: software tools for the identification of MoRFs in protein sequences. Nucleic Acids Res. 44, W488\u2013W493 (2016).","journal-title":"Nucleic Acids Res."},{"key":"2932_CR68","doi-asserted-by":"publisher","first-page":"e2406407121","DOI":"10.1073\/pnas.2406407121","volume":"121","author":"A Omidi","year":"2024","unstructured":"Omidi, A., M\u00f8ller, M. H., Malhis, N., Bui, J. M. & Gsponer, J. AlphaFold-Multimer accurately captures interactions and dynamics of intrinsically disordered protein regions. Proc. Natl. Acad. Sci. USA 121, e2406407121 (2024).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2932_CR69","doi-asserted-by":"publisher","first-page":"e70426","DOI":"10.1002\/pro.70426","volume":"35","author":"M Mehdiabadi","year":"2026","unstructured":"Mehdiabadi, M., Tosatto, S. C. E. & Piovesan, D. Modeling intrinsically disordered regions from AlphaFold2 to AlphaFold3. Protein Sci. 35, e70426 (2026).","journal-title":"Protein Sci."},{"key":"2932_CR70","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1038\/s41417-024-00763-x","volume":"31","author":"D Ronchetti","year":"2024","unstructured":"Ronchetti, D. et al. The pleiotropic nature of NONO, a master regulator of essential biological pathways in cancers. Cancer Gene Ther. 31, 984\u2013994 (2024).","journal-title":"Cancer Gene Ther."},{"key":"2932_CR71","doi-asserted-by":"publisher","first-page":"15779","DOI":"10.1073\/pnas.0808480105","volume":"105","author":"CY Jao","year":"2008","unstructured":"Jao, C. Y. & Salic, A. Exploring RNA transcription and turnover in vivo by using click chemistry. Proc. Natl. Acad. Sci. USA 105, 15779\u201315784 (2008).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2932_CR72","doi-asserted-by":"crossref","unstructured":"Dvo\u0159\u00e1\u010dkov\u00e1, M. & Fajkus, J. Visualization of the Nucleolus Using 5\u2032 Ethynyl Uridine. in Plant Cytogenetics and Cytogenomics: Methods and Protocols (eds. Heitkam, T. & Garcia, S.) 377\u2013385 (Springer US, 2023).","DOI":"10.1007\/978-1-0716-3226-0_24"},{"key":"2932_CR73","doi-asserted-by":"publisher","first-page":"100865","DOI":"10.1016\/j.xpro.2021.100865","volume":"2","author":"L Martin","year":"2021","unstructured":"Martin, L. et al. A protocol to quantify chromatin compaction with confocal and super-resolution microscopy in cultured cells. STAR Protoc. 2, 100865 (2021).","journal-title":"STAR Protoc."},{"key":"2932_CR74","doi-asserted-by":"publisher","first-page":"4151","DOI":"10.1093\/nar\/gkae069","volume":"52","author":"JA Espinoza","year":"2024","unstructured":"Espinoza, J. A. et al. Chromatin damage generated by DNA intercalators leads to degradation of RNA Polymerase II. Nucleic Acids Res. 52, 4151\u20134166 (2024).","journal-title":"Nucleic Acids Res."},{"key":"2932_CR75","doi-asserted-by":"publisher","first-page":"2126","DOI":"10.3390\/cancers14092126","volume":"14","author":"A Zisi","year":"2022","unstructured":"Zisi, A., Bartek, J. & Lindstr\u00f6m, M. S. Targeting ribosome biogenesis in cancer: lessons learned and way forward. Cancers 14, 2126 (2022).","journal-title":"Cancers"},{"key":"2932_CR76","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1158\/0008-5472.CAN-10-1728","volume":"71","author":"D Drygin","year":"2011","unstructured":"Drygin, D. et al. Targeting RNA polymerase I with an oral small molecule CX-5461 inhibits ribosomal RNA synthesis and solid tumor growth. Cancer Res. 71, 1418\u20131430 (2011).","journal-title":"Cancer Res."},{"key":"2932_CR77","doi-asserted-by":"publisher","DOI":"10.1172\/JCI193745","volume":"135","author":"Y Bao","year":"2025","unstructured":"Bao, Y. et al. CDK12\/13 inactivation triggers STING-mediated antitumor immunity in preclinical models. J. Clin. Investig. 135, e193745 (2025).","journal-title":"J. Clin. Investig."},{"key":"2932_CR78","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1038\/s41568-022-00503-z","volume":"22","author":"LE Kandalaft","year":"2022","unstructured":"Kandalaft, L. E., Dangaj Laniti, D. & Coukos, G. Immunobiology of high-grade serous ovarian cancer: lessons for clinical translation. Nat. Rev. Cancer 22, 640\u2013656 (2022).","journal-title":"Nat. Rev. Cancer"},{"key":"2932_CR79","doi-asserted-by":"publisher","first-page":"101758","DOI":"10.1016\/j.xcrm.2024.101758","volume":"5","author":"JC-Y Tien","year":"2024","unstructured":"Tien, J. C.-Y. et al. CDK12 loss drives prostate cancer progression, transcription-replication conflicts, and synthetic lethality with paralog CDK13. Cell Rep. Med. 5, 101758 (2024).","journal-title":"Cell Rep. Med."},{"key":"2932_CR80","first-page":"684","volume":"40","author":"Y Wang","year":"2026","unstructured":"Wang, Y. et al. Loss of the tumor suppressor PTEN activates cell-intrinsic interferon signaling to drive immune resistance. Genes Dev. 40, 684\u2013698 (2026).","journal-title":"Genes Dev."},{"key":"2932_CR81","doi-asserted-by":"publisher","first-page":"9","DOI":"10.3390\/jox16010009","volume":"16","author":"M Cecati","year":"2026","unstructured":"Cecati, M. et al. Cisplatin as a xenobiotic agent: molecular mechanisms of actions and clinical applications in oncology. J. Xenobiotics 16, 9 (2026).","journal-title":"J. Xenobiotics"},{"key":"2932_CR82","doi-asserted-by":"publisher","first-page":"zcaa003","DOI":"10.1093\/narcan\/zcaa003","volume":"2","author":"K Pilarova","year":"2020","unstructured":"Pilarova, K., Herudek, J. & Blazek, D. CDK12: cellular functions and therapeutic potential of versatile player in cancer. NAR Cancer 2, zcaa003 (2020).","journal-title":"NAR Cancer"},{"key":"2932_CR83","doi-asserted-by":"publisher","first-page":"6698","DOI":"10.1093\/nar\/gkx187","volume":"45","author":"JF Tien","year":"2017","unstructured":"Tien, J. F. et al. CDK12 regulates alternative last exon mRNA splicing and promotes breast cancer cell invasion. Nucleic Acids Res. 45, 6698\u20136716 (2017).","journal-title":"Nucleic Acids Res."},{"key":"2932_CR84","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1016\/j.molcel.2011.10.013","volume":"44","author":"A Helmrich","year":"2011","unstructured":"Helmrich, A., Ballarino, M. & Tora, L. Collisions between replication and transcription complexes cause common fragile site instability at the longest human genes. Mol. Cell 44, 966\u2013977 (2011).","journal-title":"Mol. Cell"},{"key":"2932_CR85","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1080\/15476286.2023.2242649","volume":"20","author":"K Basu","year":"2023","unstructured":"Basu, K., Dey, A. & Kiran, M. Inefficient splicing of long non-coding RNAs is associated with higher transcript complexity in human and mouse. RNA Biol. 20, 563\u2013572 (2023).","journal-title":"RNA Biol."},{"key":"2932_CR86","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1016\/j.tig.2021.03.010","volume":"37","author":"MR Khan","year":"2021","unstructured":"Khan, M. R., Wellinger, R. J. & Laurent, B. Exploring the alternative splicing of long noncoding RNAs. Trends Genet. 37, 695\u2013698 (2021).","journal-title":"Trends Genet."},{"key":"2932_CR87","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1038\/s41422-024-00975-8","volume":"34","author":"L Poliseno","year":"2024","unstructured":"Poliseno, L., Lanza, M. & Pandolfi, P. P. Coding, or non-coding, that is the question. Cell Res. 34, 609\u2013629 (2024).","journal-title":"Cell Res."},{"key":"2932_CR88","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1038\/s41580-023-00673-0","volume":"25","author":"AS Holehouse","year":"2024","unstructured":"Holehouse, A. S. & Kragelund, B. B. The molecular basis for cellular function of intrinsically disordered protein regions. Nat. Rev. Mol. Cell Biol. 25, 187\u2013211 (2024).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"2932_CR89","doi-asserted-by":"publisher","first-page":"11092","DOI":"10.1021\/jacs.0c03217","volume":"142","author":"P Robustelli","year":"2020","unstructured":"Robustelli, P., Piana, S. & Shaw, D. E. Mechanism of Coupled Folding-upon-Binding of an Intrinsically Disordered Protein. J. Am. Chem. Soc. 142, 11092\u201311101 (2020).","journal-title":"J. Am. Chem. Soc."},{"key":"2932_CR90","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1038\/s41392-024-02070-1","volume":"10","author":"S Jeon","year":"2025","unstructured":"Jeon, S. et al. Emerging regulatory mechanisms and functions of biomolecular condensates: implications for therapeutic targets. Signal Transduct. Target. Ther. 10, 4 (2025).","journal-title":"Signal Transduct. Target. Ther."},{"key":"2932_CR91","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.canlet.2015.03.040","volume":"362","author":"C Kreuzinger","year":"2015","unstructured":"Kreuzinger, C. et al. Molecular characterization of 7 new established cell lines from high grade serous ovarian cancer. Cancer Lett. 362, 218\u2013228 (2015).","journal-title":"Cancer Lett."},{"key":"2932_CR92","doi-asserted-by":"publisher","first-page":"W739","DOI":"10.1093\/nar\/gkac382","volume":"50","author":"A Ianevski","year":"2022","unstructured":"Ianevski, A., Giri, A. K. & Aittokallio, T. SynergyFinder 3.0: an interactive analysis and consensus interpretation of multi-drug synergies across multiple samples. Nucleic Acids Res. 50, W739\u2013W743 (2022).","journal-title":"Nucleic Acids Res."},{"key":"2932_CR93","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1038\/s42256-019-0122-4","volume":"1","author":"A Ianevski","year":"2019","unstructured":"Ianevski, A. et al. Prediction of drug combination effects with a minimal set of experiments. Nat. Mach. Intell. 1, 568\u2013577 (2019).","journal-title":"Nat. Mach. Intell."},{"key":"2932_CR94","doi-asserted-by":"publisher","first-page":"6734","DOI":"10.1128\/MCB.25.15.6734-6746.2005","volume":"25","author":"E Rosonina","year":"2005","unstructured":"Rosonina, E. et al. Role for PSF in mediating transcriptional activator-dependent stimulation of pre-mRNA processing in vivo. Mol. Cell. Biol. 25, 6734\u20136746 (2005).","journal-title":"Mol. Cell. Biol."},{"key":"2932_CR95","doi-asserted-by":"publisher","first-page":"2591","DOI":"10.1242\/jcs.114.14.2591","volume":"114","author":"TK Ko","year":"2001","unstructured":"Ko, T. K., Kelly, E. & Pines, J. CrkRS: a novel conserved Cdc2-related protein kinase that colocalises with SC35 speckles. J. Cell Sci. 114, 2591\u20132603 (2001).","journal-title":"J. Cell Sci."},{"key":"2932_CR96","doi-asserted-by":"publisher","first-page":"2281","DOI":"10.1038\/nprot.2013.143","volume":"8","author":"FA Ran","year":"2013","unstructured":"Ran, F. A. et al. Genome engineering using the CRISPR-Cas9 system. Nat. Protoc. 8, 2281\u20132308 (2013).","journal-title":"Nat. Protoc."},{"key":"2932_CR97","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/nbt.1754","volume":"29","author":"JT Robinson","year":"2011","unstructured":"Robinson, J. T. et al. Integrative genomics viewer. Nat. Biotechnol. 29, 24\u201326 (2011).","journal-title":"Nat. Biotechnol."},{"key":"2932_CR98","doi-asserted-by":"publisher","first-page":"btac830","DOI":"10.1093\/bioinformatics\/btac830","volume":"39","author":"JT Robinson","year":"2023","unstructured":"Robinson, J. T., Thorvaldsdottir, H., Turner, D. & Mesirov, J. P. igv.js: an embeddable JavaScript implementation of the Integrative Genomics Viewer (IGV). Bioinforma. Oxf. Engl. 39, btac830 (2023).","journal-title":"Bioinforma. Oxf. Engl."},{"key":"2932_CR99","doi-asserted-by":"publisher","first-page":"1978","DOI":"10.1093\/bioinformatics\/bty897","volume":"35","author":"C Kopanos","year":"2019","unstructured":"Kopanos, C. et al. VarSome: the human genomic variant search engine. Bioinforma. Oxf. Engl. 35, 1978\u20131980 (2019).","journal-title":"Bioinforma. Oxf. Engl."},{"key":"2932_CR100","doi-asserted-by":"publisher","DOI":"10.1038\/s41597-024-03327-8","volume":"11","author":"H Tordai","year":"2024","unstructured":"Tordai, H. et al. Analysis of AlphaMissense data in different protein groups and structural context. Sci. Data 11, 495 (2024).","journal-title":"Sci. Data"},{"key":"2932_CR101","doi-asserted-by":"publisher","first-page":"3140","DOI":"10.1002\/ijc.32369","volume":"145","author":"JT Fekete","year":"2019","unstructured":"Fekete, J. T. & Gy\u0151rffy, B. ROCplot.org: Validating predictive biomarkers of chemotherapy\/hormonal therapy\/anti-HER2 therapy using transcriptomic data of 3104 breast cancer patients. Int. J. Cancer 145, 3140\u20133151 (2019).","journal-title":"Int. J. Cancer"},{"key":"2932_CR102","doi-asserted-by":"publisher","first-page":"2943","DOI":"10.1093\/bioinformatics\/btac166","volume":"38","author":"GH Putri","year":"2022","unstructured":"Putri, G. H., Anders, S., Pyl, P. T., Pimanda, J. E. & Zanini, F. Analysing high-throughput sequencing data in Python with HTSeq 2.0. Bioinformatics 38, 2943\u20132945 (2022).","journal-title":"Bioinformatics"},{"key":"2932_CR103","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-014-0550-8","volume":"15","author":"MI Love","year":"2014","unstructured":"Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550 (2014).","journal-title":"Genome Biol."},{"key":"2932_CR104","first-page":"275","volume":"18","author":"M Stephens","year":"2017","unstructured":"Stephens, M. False discovery rates: a new deal. Biostatistics 18, 275\u2013294 (2017).","journal-title":"Biostatistics"},{"key":"2932_CR105","doi-asserted-by":"publisher","first-page":"2847","DOI":"10.1093\/bioinformatics\/btw313","volume":"32","author":"Z Gu","year":"2016","unstructured":"Gu, Z., Eils, R. & Schlesner, M. Complex heatmaps reveal patterns and correlations in multidimensional genomic data. Bioinformatics 32, 2847\u20132849 (2016).","journal-title":"Bioinformatics"},{"key":"2932_CR106","volume":"2","author":"T Wu","year":"2021","unstructured":"Wu, T. et al. clusterProfiler 4.0: A universal enrichment tool for interpreting omics data. Innovation 2, 100141 (2021).","journal-title":"Innovation"},{"key":"2932_CR107","doi-asserted-by":"publisher","first-page":"E5593","DOI":"10.1073\/pnas.1419161111","volume":"111","author":"S Shen","year":"2014","unstructured":"Shen, S. et al. rMATS: Robust and flexible detection of differential alternative splicing from replicate RNA-Seq data. Proc. Natl. Acad. Sci. USA 111, E5593\u2013E5601 (2014).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2932_CR108","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1038\/s41596-023-00944-2","volume":"19","author":"Y Wang","year":"2024","unstructured":"Wang, Y. et al. rMATS-turbo: an efficient and flexible computational tool for alternative splicing analysis of large-scale RNA-seq data. Nat. Protoc. 19, 1083\u20131104 (2024).","journal-title":"Nat. Protoc."},{"key":"2932_CR109","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/8902428","volume":"2021","author":"JC Brown","year":"2021","unstructured":"Brown, J. C. Role of gene length in control of human gene expression: chromosome-specific and tissue-specific effects. Int. J. Genomics 2021, 8902428 (2021).","journal-title":"Int. J. Genomics"},{"key":"2932_CR110","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/s41592-023-02159-5","volume":"21","author":"JM Lotthammer","year":"2024","unstructured":"Lotthammer, J. M., Ginell, G. M., Griffith, D., Emenecker, R. J. & Holehouse, A. S. Direct prediction of intrinsically disordered protein conformational properties from sequence. Nat. Methods 21, 465\u2013476 (2024).","journal-title":"Nat. Methods"},{"key":"2932_CR111","doi-asserted-by":"crossref","unstructured":"Lotthammer, J. M. et al. Metapredict enables accurate disorder prediction across the Tree of Life. bioRxiv 2024.11.05.622168 Preprint (2024).","DOI":"10.2139\/ssrn.5026633"}],"container-title":["Signal Transduction and Targeted Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02932-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02932-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02932-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T23:01:39Z","timestamp":1788390099000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02932-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,3]]},"references-count":111,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2932"],"URL":"https:\/\/doi.org\/10.1038\/s41392-026-02932-w","relation":{},"ISSN":["2059-3635"],"issn-type":[{"value":"2059-3635","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,3]]},"assertion":[{"value":"20 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ashwani Bahl is Chief Scientific Officer of Carrick Therapeutics. The other authors declare that they have no conflicts of interest related to this manuscript.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"361"}}